First Foundation Advisors Amgen Inc Transaction History

First Foundation Advisors

  • $2.58 Billion
  • Q3 2024

A detailed history of First Foundation Advisors transactions in Amgen Inc stock. As of the latest transaction made, First Foundation Advisors holds 3,314 shares of AMGN stock, worth $974,316. This represents 0.04% of its overall portfolio holdings.

Number of Shares
3,314
Previous 3,463 4.3%
Holding current value
$974,316
Previous $1.08 Million 1.39%
% of portfolio
0.04%
Previous 0.04%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
SELL
$309.38 - $337.38 $46,097 - $50,269
-149 Reduced 4.3%
3,314 $1.07 Million
Q2 2024

Aug 06, 2024
SELL
$262.75 - $319.31 $4,992 - $6,066
-19 Reduced 0.55%
3,463 $1.08 Million
Q1 2024

May 09, 2024
SELL
$268.87 - $324.56 $3,226 - $3,894
-12 Reduced 0.34%
3,482 $990,000
Q4 2023

Feb 14, 2024
SELL
$255.7 - $288.46 $345,450 - $389,709
-1,351 Reduced 27.88%
3,494 $1.01 Million
Q3 2023

Nov 15, 2023
BUY
$218.65 - $271.46 $125,505 - $155,818
574 Added 13.44%
4,845 $1.3 Million
Q2 2023

Aug 14, 2023
SELL
$214.27 - $253.37 $190,700 - $225,499
-890 Reduced 17.24%
4,271 $948,000
Q1 2023

May 12, 2023
BUY
$225.79 - $275.2 $80,155 - $97,696
355 Added 7.39%
5,161 $1.25 Million
Q4 2022

Feb 14, 2023
BUY
$229.03 - $291.01 $166,275 - $211,273
726 Added 17.79%
4,806 $1.26 Million
Q3 2022

Nov 10, 2022
BUY
$224.46 - $253.15 $2,020 - $2,278
9 Added 0.22%
4,080 $920,000
Q2 2022

Aug 12, 2022
SELL
$230.71 - $256.74 $112,586 - $125,289
-488 Reduced 10.7%
4,071 $991,000
Q1 2022

May 05, 2022
SELL
$219.27 - $242.57 $125,203 - $138,507
-571 Reduced 11.13%
4,559 $1.1 Million
Q4 2021

Feb 14, 2022
BUY
$198.88 - $227.6 $89,098 - $101,964
448 Added 9.57%
5,130 $1.15 Million
Q3 2021

Nov 15, 2021
SELL
$212.27 - $248.7 $89,365 - $104,702
-421 Reduced 8.25%
4,682 $996,000
Q2 2021

Aug 13, 2021
SELL
$233.58 - $259.14 $277,025 - $307,340
-1,186 Reduced 18.86%
5,103 $1.24 Million
Q1 2021

May 18, 2021
SELL
$221.91 - $258.6 $8.22 Million - $9.58 Million
-37,061 Reduced 85.49%
6,289 $1.57 Million
Q4 2020

Feb 16, 2021
BUY
$216.38 - $257.67 $225,035 - $267,976
1,040 Added 2.46%
43,350 $9.97 Million
Q3 2020

Nov 12, 2020
BUY
$234.65 - $260.95 $8.22 Million - $9.14 Million
35,042 Added 482.14%
42,310 $10.8 Million
Q2 2020

Aug 14, 2020
BUY
$197.81 - $242.74 $39,562 - $48,548
200 Added 2.83%
7,268 $1.71 Million
Q1 2020

May 11, 2020
BUY
$182.24 - $241.7 $51,209 - $67,917
281 Added 4.14%
7,068 $1.43 Million
Q4 2019

Feb 11, 2020
BUY
$189.21 - $243.2 $458,455 - $589,273
2,423 Added 55.52%
6,787 $1.64 Million
Q3 2019

Nov 12, 2019
BUY
$174.11 - $208.62 $166,275 - $199,232
955 Added 28.01%
4,364 $845,000
Q2 2019

Aug 14, 2019
BUY
$166.7 - $195.41 $68,180 - $79,922
409 Added 13.63%
3,409 $628,000
Q1 2019

May 13, 2019
BUY
$180.87 - $203.88 $8,139 - $9,174
45 Added 1.52%
3,000 $570,000
Q4 2018

Feb 14, 2019
SELL
$178.4 - $208.25 $37,820 - $44,149
-212 Reduced 6.69%
2,955 $575,000
Q3 2018

Nov 13, 2018
SELL
$185.29 - $208.89 $218,827 - $246,699
-1,181 Reduced 27.16%
3,167 $656,000
Q2 2018

Aug 14, 2018
SELL
$166.05 - $186.51 $54,796 - $61,548
-330 Reduced 7.05%
4,348 $803,000
Q1 2018

May 15, 2018
BUY
$169.43 - $198.0 $73,532 - $85,932
434 Added 10.23%
4,678 $797,000
Q4 2017

Feb 14, 2018
BUY
$168.79 - $188.59 $14,853 - $16,595
88 Added 2.12%
4,244 $738,000
Q3 2017

Nov 14, 2017
BUY
$167.29 - $191.0 $83,645 - $95,500
500 Added 13.68%
4,156 $775,000
Q2 2017

Aug 14, 2017
BUY
N/A
3,656
3,656 $630,000

Others Institutions Holding AMGN

# of Institutions
3,123
Shares Held
409M
Call Options Held
7.56M
Put Options Held
7.2M
View Full List

About AMGEN INC

AMGN Quotes by TradingView
  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $157B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track First Foundation Advisors Portfolio

Follow First Foundation Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Foundation Advisors, based on Form 13F filings with the SEC.

News

Stay updated on First Foundation Advisors with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email